Zulvac 1 Ovis

inactivated bluetongue virus, serotype-1

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

What is Zulvac 1 Ovis?

Zulvac 1 Ovis is a vaccine that is available as a suspension for injection. It contains inactivated (killed) bluetongue serotype-1 virus.

What is Zulvac 1 Ovis used for?

Zulvac 1 Ovisis used in sheep to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges. The vaccine is used to prevent viraemia (the presence of the viruses in the blood) in sheep from one and a half months of age.

The vaccine is given to young animals as two injections under the skin. The first injection is given from one and a half months of age and the second injection is given three weeks later. Protection starts three weeks after the last injection and lasts for a year.

How does Zulvac 1 Ovis work?

Zulvac 1 Ovis is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. Zulvac 1 Ovis contains bluetongue viruses that have been inactivated so that they cannot cause the disease. When it is given to sheep, the immune system recognises the viruses as ‘foreign’ and makes antibodies against them. In the future, if the animals are exposed to the bluetongue virus, the immune system will be able to produce antibodies more quickly. This will help to protect against the disease.

Zulvac 1 Bovis contains bluetongue virus of one serotype (serotype-1). The vaccine also contains ‘adjuvants’ (aluminium hydroxide and saponin) to enhance the immune response.

How has Zulvac 1 Ovis been studied?

The safety of the vaccine was studied in two main laboratory safety studies carried out in sheep and two studies carried out in pregnant ewes.

The effectiveness of the vaccine was studied in three main laboratory studies in lambs from one month of age. The animals were challenged with bluetongue virus serotype-1, after receiving Zulvac 1 Bovis vaccine containing different amounts of virus. The studies goal was to establish the smallest dose of vaccine that prevented viraemia as well as the duration of protection for Zulvac 1 Ovis.

What benefit has Zulvac 1 Ovis shown during the studies?

The studies showed that the vaccine prevents viraemia in sheep and offered protection for one year. The vaccine is safe for sheep from one and a half months of age onwards and in pregnant ewes.

The vaccine was generally well tolerated and shown to be safe.

What is the risk associated with Zulvac 1 Ovis?

Following vaccination sheep may have a slightly raised body temperature. They may also have a swelling at the injection site lasting no more than seven days or a hardening under the skin (nodules), which could last more than six or seven weeks.

What is the withdrawal period?

The withdrawal period is the time allowed after administration of the medicine before the animal can be slaughtered and the meat or milk used for human consumption. The withdrawal period for Zulvac 1 Ovis for meat and milk is zero days.

Why has Zulvac 1 Ovis been approved?

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Zulvac 1 Ovis exceed the risks in the prevention of viraemia caused by bluetongue virus, serotype-1 in sheep from one and a half months of age. The benefit-risk balance may be found in the scientific discussion module of this EPAR.

Zulvac 1 Ovis was initially authorised under ‘exceptional circumstances’. This means that it was not possible to obtain complete information about Zulvac 1 Ovis at the time of the initial authorisation. The European Medicines Agency has reviewed additional information submitted according to an agreed timetable on the quality and safety of the vaccine. In 2012, the CVMP considered that the submitted data were adequate for the authorisation of Zulvac 1 Ovis to convert to normal.

Other information about Zulvac 1 Ovis

The European Commission granted a marketing authorisation valid throughout the European Union, for Zulvac 1 Ovis on 5 August 2011. Information on the prescription status of this product may be found on the label / outer package.

Name Language First published Last updated
Zulvac 1 Ovis : EPAR - Summary for the public BG = bălgarski 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public ES = español 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public CS = čeština 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public DA = dansk 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public DE = Deutsch 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public ET = eesti keel 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public EL = elliniká 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public EN = English 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public FR = français 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public IT = italiano 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public LV = latviešu valoda 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public LT = lietuvių kalba 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public HU = magyar 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public MT = Malti 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public NL = Nederlands 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public PL = polski 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public PT = português 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public RO = română 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public SK = slovenčina 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public SL = slovenščina 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public FI = suomi 2011-10-10 2013-06-04
Zulvac 1 Ovis : EPAR - Summary for the public SV = svenska 2011-10-10 2013-06-04

This EPAR was last updated on 11/04/2017 .

Authorisation details

Product details

Product details for Zulvac 1 Ovis
NameZulvac 1 Ovis
Agency product numberEMEA/V/C/002335
Active substance

inactivated bluetongue virus, serotype-1

International non-proprietary name (INN) or common name

inactivated bluetongue virus, serotype-1

Species Sheep
Anatomical therapeutic chemical veterinary (ATCvet) codes QI04AA02




Accelerated procedure

Accelerated procedures are intended to speed up access to new medicines of major public-health interest. Eligible products must either responds to unmet medical needs or constitute a significant improvement over the available methods of prevention, diagnosis or treatment of a condition.

Publication details

Publication details for Zulvac 1 Ovis
Marketing-authorisation holder

Zoetis Belgium SA

Revision5
Date of issue of marketing authorisation valid throughout the European Union05/08/2011

Contact address:

Zoetis Belgium SA
Rue Laid Burniat 1
1348
Louvain-la-Neuve
Belgium

Product information

Product information

23/03/2017  Zulvac 1 Ovis -EMEA/V/C/002335 -IG/0747

Name Language First published Last updated
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11
Zulvac 1 Ovis : EPAR - Product information SV = svenska 2011-10-10 2017-04-11

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  
Zulvac 1 Ovis : EPAR - All authorised presentations SV = svenska 2011-10-10  

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: 12 months.

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
Zulvac 1 Ovis : EPAR - Scientific discussion SV = svenska 2011-10-10  
CVMP summary of positive opinion for Zulvac 1 Ovis SV = svenska 2011-06-10